Journal of Clinical & Experimental Pathology
Open Access

Commentary

Lactate Dehydrogenase-5 (Ldh-5) Immunohistochemical Expression as Predictor of Efficacy of First-Line Therapy in Patients with Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab

Garde-Noguera J^1*, Gil-Raga M², Evgenyeva E³, Bernet L⁴, Llombart-Cussac A¹ and Camps-Herrer C⁵

¹Medical Oncology Department, Hospital Arnau de Vilanova, Valencia, Spain

²Medical Oncology Department, Hospital de Sagunto, Valencia, Spain

³Anatomic Pathology Department, Hospital Marina Salud, Denia, Spain

⁴Anatomic Pathology Department, Hospital Arnau de Vilanova, Valencia, Spain

⁵Medical Oncology Department, Hospital General Universitario de Valencia, Spain

*Corresponding Author:

Javier Garde-Noguera
Medical Oncology Department
Hospital Arnau de Vilanova
Valencia, Spain
Tel: 34699307265
E-mail: javiergarde@icloud.com

Received date: August 19, 2016; Accepted date: September 13, 2016; Published date: September 15, 2016

Citation: Garde-Noguera J, Gil-Raga M, Evgenyeva E, Bernet L, Llombart-Cussac A, et al. (2016) Lactate Dehydrogenase-5 (Ldh-5) Immunohistochemical Expression as Predictor of Efficacy of First-Line Therapy in Patients with Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab. J Clin Exp Pathol 6: 293. doi:10.4172/2161-0681.1000293

Copyright: © 2016 Garde-Noguera J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Purpose: The aim of this study is to analyse the prognostic role of LDH5 expression measured by immunohistochemistry in patients with advanced colorectal cancer treated with standard chemotherapy with or without bevacizumab. Methods: Retrospective multicentre study, carried out at four hospitals in the Valencian Community (Spain). We investigated the immunohistochemical expression of LDH-5 in a series of 112 patients with advanced colorectal adenocarcinomas treated with oxaliplatin-based chemotherapy with or without bevacizumab. Results: Histological samples for the LDH5 analysis were available for 87 of the 112 patients selected. Sixteen (18.3%) had undetectable or mild expression of LDH5 (Group 1) and 71 (87.7%) showed moderate or high expression of LDH5 (Group 2). Response rate in Group 1 was 56.2% compared to 60.8% in Group 2 (p=0.47). Progression-free survival (PFS) 11 vs. 12 months (p=0.28), and overall survival (OS) 20 vs. 24 months, (p=0.17), were numerically but not significantly higher in patients from Group 2 vs. Group 1. Patients from Group 2 who received bevacizumab presented a significantly higher PFS (13 vs. 12, p=0.039) and a numerically higher OS (27 vs. 20 months, p=0.27) than those treated exclusively with chemotherapy. Conclusions: Our results suggest that the absence or low expression of LDH5 is not associated with a better prognostic profile in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab. Patients with high expression of LDH5, benefit from the combination of chemotherapy with bevacizumab.

Keywords